The Burden of ACS in India
India bears the world's largest burden of Acute Coronary Syndrome (ACS). While global guidelines advocate for high-intensity statin therapy (Atorvastatin 80mg), real-world data regarding adherence and outcomes specifically within the Indian demographic is scarce. This registry fills a critical evidence gap.
Lipid Control Gap (Baseline Estimation)
Current estimated percentage of ACS patients in India achieving aggressive LDL-C targets (<55 mg/dL) pre-registry.
High Morbidity
ACS is a leading cause of mortality. Younger onset age in Indians requires aggressive secondary prevention.
Guideline vs. Practice
ACC/AHA 2025 guidelines mandate high-intensity statins. We need to measure how often this is prescribed and tolerated in Tier 2/3 Indian cities.
Socioeconomic Barriers
Cost and access significantly impact adherence. This registry specifically tracks "Out of Pocket" expenditure and medication persistence.
Study Design & Workflow
A prospective, multicenter observational registry across 20 sites. The workflow emphasizes capturing data at critical transition points of care: Admission, Discharge, and Follow-up (1, 3, and 6 months).
Hospital Admission
Screening & Consent.
Intervention (PCI)
Primary or Elective PCI.
Discharge
Education & Prescription.
Follow-Up
1, 3, & 6 Months.
Core Objectives
Primary Objective
Characterize real-world care and outcomes. Specifically tracking hospital readmissions and revascularization procedures within the first 6 months.
Adherence & Persistence
Assess adherence to High-Dose Atorvastatin using standardized queries. Identify reasons for discontinuation (Cost, Side effects, Physician advice).
Lipid Goals
Evaluate the proportion of patients achieving guideline-directed LDL-C targets at the 6-month mark post-PCI.
Anticipated Barriers to Adherence
Projected distribution of reasons for statin discontinuation in the Indian real-world setting.
Site Stratification
Target distribution of participating centers to ensure rural and semi-urban representation.
Projected LDL-C Trajectory
Target therapeutic response curve for patients on Atorvastatin 80mg from Baseline to 6 Months.
Project Timeline
1
Months 1-3
Site selection, ethics committee approvals, and staff training.
2
Months 4-21
Active Patient Enrollment (Target: ~110 patients/month).
3
Month 28+
Data cleaning, analysis, manuscript preparation, and dissemination.